Scroll for more

Manufacturing

 

株式会社アールテック・ウエノは Sucampo Pharmaceuticals, Inc. の完全子会社となりました。詳細は、Sucampo Pharmaceuticals, Inc. のホームページを(www.sucampo.com)をご覧ください。

R-Tech Ueno, Ltd. has been acquired by Sucampo Pharmaceuticals, Inc. For more information, please visit www.sucampo.com.

SUCAMPO

 平成27年12月期末 決算書類は、こちらをご覧ください。
 【電子公告】
特定の根拠法令に基づき開示するものです。
外部に専用ページを設けています。

 【お問い合わせ先】
株式会社アールテック・ウエノ ビジネスマネジメント部
TEL: 03-3596-8011(代表) / E-mail: info@rtueno.co.jp

 

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.